Skip to main content

Table 2 Distribution of the study population by lipid-lowering therapy (LLT) intensity initiated during hospitalization, at 6-month and 12-month follow-up, and low-density lipoprotein cholesterol (LDL-C) goal attainment at 6-month and 12-month follow-up (1 January 2010–31 December 2015)

From: Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study

 

LDL-C (mmol/L)

 

6-month follow-upd (N = 2242)

12-month follow-upe (N = 1547)

LLT

Total

< 1.8

≥1.8

Total

< 1.8

≥1.8

Before or during index hospitalizationa

2242

912 (40.7)

1330 (59.3)

1547

604 (39.0)

943 (61.0)

 None

173 (7.7)

34 (19.7)

139 (80.3)

122 (7.9)

25 (20.5)

97 (79.5)

 Moderateb

1888 (84.2)

801 (42.4)

1087 (57.6)

1282 (82.9)

519 (40.5)

763 (59.5)

 Intensivec

181 (8.1)

77 (42.5)

104 (57.5)

143 (9.2)

60 (42.0)

83 (58.0)

LLT

Before or during index hospitalizationa

6-month follow-up

      

 None

None

120/173 (69.4)

17/120 (14.2)

103/120 (85.8)

89/122 (73.0)

11/89 12.4)

78/89 (87.6)

Moderateb

46/173 (26.6)

< 15

< 35

28/122 (23.0)

< 15

< 20

Intensivec

7/173

(4.0)

< 7

< 7

5/122 (4.1)

< 5

< 5

 Yes

None

123/2069 (5.9)

41/123 (33.3)

82/123 (66.7)

72/1425 (5.1)

19/72 (26.4)

53/72 (73.6)

Moderateb

1501/2069 (72.5)

644/1501 (42.9)

857/1501 (57.1)

1041/1425 (73.1)

425/1041 (40.8)

616/1041 (59.2)

Intensivec

445/2069 (21.5)

193/445 (43.4)

252/445 (56.6)

312/1425 (21.9)

135/312 (43.3)

177/312 (56.7)

LLT

6-month follow-up

12-month follow-up

      

 None

None

113/161 (70.2)

15/113 (13.3)

98/113 (86.7)

Moderateb

38/161 (23.6)

< 15

< 30

Intensivec

10/161 (6.2)

< 5

< 10

 Yes

None

66/1386 (4.8)

13/66 (19.7)

53/66 (80.3)

Moderateb

871/1386 (62.8)

347/871 (39.8)

524/871 (60.2)

Intensivec

449/1386 (32.4)

214/449 (47.7)

235/449 (52.3)

  1. a LLT initiated before or during index hospitalization: LLT redeemed −180 before admission to 30 days
  2. after discharge
  3. b Patients who are treated with LLT, but who are not eligible for the group of “intensive treatment” or “no LLT” treatment
  4. c Intensive LLT is defined by 1) A minimum of 2 prescription redemptions of one combination drug; OR 2) A minimum of 2 statins prescription redemptions; OR 3) A minimum of 2 statin prescription redemptions and one ezetimibe prescription redemption; OR 4) A minimum of 2 statin prescription redemptions and one other non-statin (i.e. not ezetimibe) prescription redemption
  5. d LDL-C at 6-month follow-up: LDL-C between discharge and 180 days post discharge from hospital with ACS
  6. e LDL-C at 12-month follow-up: LDL-C between 181 and 365-days post discharge from hospital with ACS